SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VRA (AMEX), Viragen INC.
VRA 2.345-3.1%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (49)10/30/1996 9:58:00 PM
From: D. L. Renaud   of 1590
 
No offense, but I think you should review the report on VRGN at The Virtual Investor site before you criticize it. It is very comprehensive and was independently prepared.

While I agree that there are negatives to the VRGN story, I haven't seen a company yet without challenges to be addressed. In the case of VRGN, the positives and the potential seem to far outweigh the negatives, including the 38 million shares outstanding. Obviously, a large number of shares out is a hurdle, but it does not necessarily preclude future shareholder value. If that were the case, I doubt that Biogen would have just split their stock, increasing their shares out to 72 million.

Since you haven't checked out the company recently, you are not likely aware of the numerous events in process that may have a dramatic effect on VRGN value in the near future. Take a look. The deal they are working on with the American Red Cross may be a blockbuster.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext